{
    "organizations": [],
    "uuid": "f7172e560319e6bc9fdc4cce207c1586470f254d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-caladrius-biosciences-receives-sak/brief-caladrius-biosciences-receives-sakigake-expedited-review-designation-in-japan-for-clbs12-for-treating-critical-limb-ischemia-idUSFWN1RN0M8",
    "ord_in_thread": 0,
    "title": "BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 42 PM / Updated 12 minutes ago BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia Reuters Staff 1 Min Read \nApril 10 (Reuters) - Caladrius Biosciences Inc: \n* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:",
    "published": "2018-04-10T15:42:00.000+03:00",
    "crawled": "2018-04-10T16:00:31.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "bioscience",
        "receives",
        "sakigake",
        "expedited",
        "review",
        "designation",
        "japan",
        "clbs12",
        "treating",
        "critical",
        "limb",
        "ischemia",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "caladrius",
        "bioscience",
        "inc",
        "caladrius",
        "bioscience",
        "receives",
        "sakigake",
        "expedited",
        "review",
        "designation",
        "japan",
        "clbs12",
        "treating",
        "critical",
        "limb",
        "ischemia",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}